Patents Assigned to Nippon Shinyaku Co., Ltd.
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20200109162
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 9, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20200102343
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 2, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acid for treating amyotrophy
    Patent number: 10563199
    Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: February 18, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., KAWASAKI GAKUEN EDUCATIONAL FOUNDATION
    Inventors: Shinichiro Nakagawa, Seigo Nagata, Yoshihide Sunada, Yutaka Ohsawa, Shin-ichiro Nishimatsu
  • Antisense nucleic acids
    Patent number: 10487106
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 26, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20190315796
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 17, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acids
    Patent number: 10407461
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: September 10, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Antisense nucleic acids
    Patent number: 10385092
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 20, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20190218244
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20190211049
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: March 20, 2019
    Publication date: July 11, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20190211050
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: March 26, 2019
    Publication date: July 11, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acids
    Patent number: 10329319
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: June 25, 2019
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY
    Publication number: 20190048023
    Abstract: An object of the present invention is to provide a compound with an excellent JAK1 inhibitory activity. The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect, anti-proliferative effect and so on, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis, vasculitis, bronchial asthma, chronic obstructive pulmonary disease, eosinophilic sinusitis and nasal polyp.
    Type: Application
    Filed: February 28, 2017
    Publication date: February 14, 2019
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventor: Fumi HIGUCHI
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20190040387
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: October 16, 2018
    Publication date: February 7, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • COMPRESSION-MOLDED PREPARATION
    Publication number: 20190000765
    Abstract: An object of the present invention is to provide a compression-molded preparation which has an excellent disintegration property and can be easily produced despite the use of granules coated with a polymer coating film having a function such as masking of an unpleasant taste. A compression-molded preparation achieving the above object is characterized by including granules obtained by coating a polymer-coated, granulated substance, in which a granulated substance containing a drug is coated with a polymer coating film, with one kind or two or more kinds of additives selected from the group consisting of a metal stearate, stearic acid, a sucrose fatty acid ester, talc, and silicic acid.
    Type: Application
    Filed: December 26, 2016
    Publication date: January 3, 2019
    Applicant: Nippon Shinyaku Co., Ltd.
    Inventors: Naoto HATTORI, Akihito YASUDA, Hitoshi SASAKI, Yoichi ONUKI, Ryoichi OSAWA
  • Antisense nucleic acids
    Patent number: 10144931
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 4, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
  • PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSULFONYL)ACETAMIDE
    Publication number: 20180333413
    Abstract: A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.
    Type: Application
    Filed: December 1, 2016
    Publication date: November 22, 2018
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventors: Shouji FURUTA, Hironori MUKAI
  • PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSULFONYL)ACETAMIDE
    Publication number: 20180325895
    Abstract: A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.
    Type: Application
    Filed: July 25, 2018
    Publication date: November 15, 2018
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventors: Shouji FURUTA, Hironori MUKAI
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180265866
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: September 15, 2016
    Publication date: September 20, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • ANTISENSE NUCLEIC ACID FOR TREATING AMYOTROPHY
    Publication number: 20180251760
    Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 6, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., Kawasaki Gakuen Educational Foundation
    Inventors: Shinichiro NAKAGAWA, Seigo NAGATA, Yoshihide SUNADA, Yutaka OHSAWA, Shin-ichiro NISHIMATSU
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180179538
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: February 22, 2018
    Publication date: June 28, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata